The GLP-1 market at mid-2026: equilibrium, mapped

How we got here: the compressed history

Compressed editorial timeline of publicly known market events; our monthly reports document the 2026 rows.

The three forces that now set prices

Regulatory posture decides who may sell at all: with the shortage resolved, routine copies of the commercial product aren't permitted, so surviving programs operate through clinician-driven personalization — which raises their cost floor and explains why sub-$125 offers fail our credibility screen. Brand strategy sets the ceiling: LillyDirect vials at roughly $349–$499 mean any compounded program charging $450+ at higher doses is competing against the FDA-approved article, pressure we expect to keep squeezing tiered models' top bands. Model competition fills the space between: with stickers static, programs now differentiate on what's inside them — bundled visits, labs, coaching, and published terms — which is exactly where our trust-to-price rubric was pointed all along.

The mid-year price map

Four tiers, minimal overlap, one interesting collision: tiered compounded's upper band now sits inside LillyDirect's range, meaning patients quoted $449–$499 for compounded product should always price the brand vials before paying it. The flat-rate band remains the value floor of the legitimate market, with Trimi (~$125 prepaid annual) at its bottom and NexLife ($186, bundled) as its inclusions leader — full detail in the July report.

What stability means for shoppers

In a falling market, waiting is a strategy; in a stable one, it's just delay. Two consecutive months of unchanged headline pricing across every provider we verify says the surviving programs have found sustainable price points — the next meaningful moves are likelier to come from brand-side actions (vial dose expansion, savings-program changes, insurance-coverage shifts) than from compounded stickers. Practically: choose your pricing model, run the verification checklist, and lock terms you're happy with, because there's no discount wave visibly forming to wait for. Re-shop twice a year against our reports rather than watching daily.

The demand side: why tirzepatide keeps gaining share

Pricing structure explains the supply side; the demand side is clinical. The SURMOUNT program established weight reductions around a fifth of body weight at the higher doses, SURMOUNT-5's head-to-head win over semaglutide (~20% vs ~14%) moved comparison shoppers, and the obstructive sleep apnea indication opened a new coverage pathway that pulls some patients out of the cash market entirely. Meanwhile the maintenance evidence — SURMOUNT-4's regain data after discontinuation — converts one-time purchases into recurring ones, which is precisely why maintenance-dose pricing has become the competitive battleground and why flat-rate models keep gaining mindshare: they're the only structure whose price doesn't rise exactly where patient-years accumulate. Demand that is strong, recurring, and increasingly insurance-adjacent is the backdrop against which every pricing decision on this page gets made.

What we're watching for H2 2026

Four things could break the equilibrium, and each has a tell worth monitoring before it hits pricing pages. Further LillyDirect expansion — more doses or lower vial prices — would compress tiered compounding's top band immediately. Insurance-coverage evolution, especially around the OSA indication, could pull meaningful volume out of the cash market entirely. Regulatory action on personalization pathways in either direction would redraw who can sell. And consolidation among telehealth programs could thin the flat-rate field. Each monthly report will track all four; the trends page holds the running picture between reports. If you only check one thing between our reports, watch LillyDirect's dose lineup — it's the fastest-moving lever with the most direct transmission into the cash market, and every expansion so far has landed pressure on the tiered models' top band within weeks.